AEMD (AETHLON MEDICAL INC)
Insider Trading Activity
Every open-market purchase and sale reported by AEMD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-01 | Chetan Shah | Director | F | — | — |
| 2026-07-01 | EDWARD G BROENNIMAN | Director | F | — | — |
| 2026-07-01 | Nicolas Gikakis | Director | F | — | — |
| 2026-04-21 | Nicolas Gikakis | Director | A | — | — |
| 2026-04-21 | EDWARD G BROENNIMAN | Director | A | — | — |
| 2026-04-21 | Angela Rossetti | Director | A | — | — |
| 2026-04-21 | Chetan Shah | Director | A | — | — |
| 2026-04-01 | EDWARD G BROENNIMAN | Director | F | — | — |
| 2026-04-01 | Chetan Shah | Director | F | — | — |
| 2026-04-01 | Nicolas Gikakis | Director | F | — | — |
| 2026-01-02 | Chetan Shah | Director | F | — | — |
| 2026-01-02 | Nicolas Gikakis | Director | F | — | — |
| 2026-01-02 | EDWARD G BROENNIMAN | Director | F | — | — |
| 2025-10-02 | Nicolas Gikakis | Director | F | — | — |
| 2025-10-02 | Chetan Shah | Director | F | — | — |
| 2025-10-02 | EDWARD G BROENNIMAN | Director | F | — | — |
| 2025-07-01 | Nicolas Gikakis | Director | F | — | — |
| 2025-07-01 | EDWARD G BROENNIMAN | Director | F | — | — |
| 2025-07-01 | Chetan Shah | Director | F | — | — |
| 2025-04-25 | Chetan Shah | Director | A | — | — |
| 2025-04-25 | EDWARD G BROENNIMAN | Director | A | — | — |
| 2025-04-25 | Angela Rossetti | Director | A | — | — |
| 2025-04-25 | Nicolas Gikakis | Director | A | — | — |
| 2025-04-01 | Nicolas Gikakis | Director | F | — | — |
| 2025-04-01 | EDWARD G BROENNIMAN | Director | F | — | — |
| 2025-04-01 | Chetan Shah | Director | F | — | — |
| 2025-01-03 | EDWARD G BROENNIMAN | Director | F | — | — |
| 2025-01-03 | Chetan Shah | Director | F | — | — |
| 2025-01-03 | Nicolas Gikakis | Director | F | — | — |
| 2024-10-01 | Nicolas Gikakis | Director | F | — | — |
| 2024-10-01 | Chetan Shah | Director | F | — | — |
| 2024-10-01 | EDWARD G BROENNIMAN | Director | F | — | — |
| 2024-07-01 | Nicolas Gikakis | Director | F | — | — |
| 2024-07-01 | EDWARD G BROENNIMAN | Director | F | — | — |
| 2024-07-01 | Chetan Shah | Director | F | — | — |
| 2024-04-17 | Nicolas Gikakis | Director | A | — | — |
| 2024-04-17 | Chetan Shah | Director | A | — | — |
| 2024-04-17 | EDWARD G BROENNIMAN | Director | A | — | — |
| 2024-04-17 | Angela Rossetti | Director | A | — | — |
| 2024-04-01 | Chetan Shah | Director | F | — | — |
| 2024-04-01 | Nicolas Gikakis | Director | F | — | — |
| 2024-04-01 | EDWARD G BROENNIMAN | Director | F | — | — |
| 2024-01-02 | Chetan Shah | Director | F | — | — |
| 2024-01-02 | Nicolas Gikakis | Director | F | — | — |
| 2024-01-02 | EDWARD G BROENNIMAN | Director | F | — | — |
| 2023-09-29 | EDWARD G BROENNIMAN | Director | F | — | — |
| 2023-09-29 | Chetan Shah | Director | F | — | — |
| 2023-09-29 | Nicolas Gikakis | Director | F | — | — |
| 2023-07-06 | Nicolas Gikakis | Director | A | — | — |
| 2023-07-03 | EDWARD G BROENNIMAN | Director | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 5,241 | — |
| — | Director | 4,473 | — |
| — | Director | 4,168 | — |
| — | Director | 4,133 | — |
| — | Director | 8 | — |
| — | Chief Executive Officer | 5 | — |
| — | Chairman, CEO, Secretary | 4 | — |
| — | Sr. V.P., Chief Bus. Officer | 4 | — |
| — | CFO & Sr. VP ? Finance | 1 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AEMD quote page; the site-wide leaderboard is on the insider transactions hub.